Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
- J. Byrd, R. Furman, +18 authors S. O'brien
- Medicine
- The New England journal of medicine
- 3 July 2013
BACKGROUND
The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling,… Expand
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- S. Neelapu, Sudhakar Tummala, +16 authors E. Shpall
- Medicine
- Nature Reviews Clinical Oncology
- 2018
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological… Expand
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
- A. Roberts, J. Seymour, +13 authors R. Humerickhouse
- Medicine
- Journal of clinical oncology : official journal…
- 10 February 2012
PURPOSE
BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w,… Expand
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
- M. Keating, S. O'Brien, +12 authors H. Kantarjian
- Medicine
- Journal of clinical oncology : official journal…
- 20 June 2005
PURPOSE
Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro in lymphoma cell… Expand
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
- A. Ferrajoli, Bang-Ning Lee, +10 authors M. Keating
- Medicine
- Blood
- 1 June 2008
This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg… Expand
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- J. Byrd, R. Furman, +13 authors S. O'brien
- Medicine
- Blood
- 16 April 2015
Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated… Expand
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
- S. Stilgenbauer, B. Eichhorst, +20 authors W. Wierda
- Medicine
- The Lancet. Oncology
- 1 June 2016
BACKGROUND
Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral… Expand
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
- Sabine Ponader, S. Chen, +7 authors J. Burger
- Biology, Medicine
- Blood
- 2 February 2012
B-cell receptor (BCR) signaling is a critical pathway in the pathogenesis of several B-cell malignancies, including chronic lymphocytic leukemia (CLL), and can be targeted by inhibitors of… Expand
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
- W. Wierda, T. Kipps, +17 authors A. Osterborg
- Medicine
- Journal of clinical oncology : official journal…
- 1 April 2010
PURPOSE
New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm)… Expand
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
- J. Burger, M. P. Quiroga, +4 authors A. Rosenwald
- Chemistry, Medicine
- Blood
- 16 November 2007
In lymphatic tissues, chronic lymphocytic leukemia (CLL) cells are interspersed with CD68(+) nurselike cells (NLCs), T cells, and other stromal cells that constitute the leukemia microenvironment.… Expand